Potential Drug-Drug Interaction (PDDI) Clinical Decision Support, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 1.0.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/PDDI-CDS/ and changes regularly. See the Directory of published versions
| Official URL: http://hl7.org/fhir/uv/pddi/ValueSet/valueset-rimexolone-exclude | Version: 1.0.0 | ||||
| Standards status: Informative | Computable Name: Valueset_rimexolone_exclude | ||||
Copyright/Legal: (copyright expectations unknown) |
|||||
ValueSet containing drug identifiers to exclude. Criteria is explicitly stating topical, gel, cream, ointment, otic, or ophthalmic formulations.
References
This value set is not used here; it may be used elsewhere (e.g. specifications and/or implementations that use this content)
http://www.nlm.nih.gov/research/umls/rxnorm version Not Stated (use latest from terminology server)| Code | Display |
| 207446 | rimexolone 10 MG/ML Ophthalmic Suspension [Vexol] |
| 365826 | rimexolone Ophthalmic Suspension [Vexol] |
| 199115 | rimexolone 10 MG/ML Ophthalmic Suspension |
| 379299 | rimexolone Ophthalmic Suspension |
| 1157440 | rimexolone Ophthalmic Product |
| 1188083 | Vexol Ophthalmic Product |
Expansion from tx.fhir.org based on codesystem RxNorm v03022026 (CodeSystem)
This value set contains 6 concepts